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Abstract
Background: Recombinant human erythropoietin (EPO) is used for the treatment of last stage
renal anemia. A new EPO preparation was obtained in Cuba in order to make this treatment fully
nationally available. The aim of this study was to compare the pharmacokinetic, pharmacodynamic
and safety properties of two recombinant EPO formulations in patients with anemia due to end-
stage renal disease on hemodialysis.
Methods: A parallel, randomized, double blind study was performed. A single 100 IU/Kg EPO dose
was administered subcutaneously. Heberitro (Heber Biotec, Havana, formulation A), a newly
developed product and Eprex (CILAG AG, Switzerland, formulation B), as reference treatment
were compared. Thirty-four patients with anemia due to end-stage renal disease on hemodialysis
were included. Patients had not received EPO previously. Serum EPO level was measured by
enzyme immunoassay (EIA) during 120 hours after administration. Clinical and laboratory variables
were determined as pharmacodynamic and safety criteria until 216 hours.
Results:  Both groups of patients were similar regarding all demographic and baseline
characteristics. EPO kinetics profiles were similar for both formulations; the pharmacokinetic
parameters were very close (i.e., AUC: 4667 vs. 4918 mIU.h/mL; Cmax: 119.1 vs. 119.7 mIU/mL;
Tmax: 13.9 vs. 18.1 h; half-life, 20.0 vs. 22.5 h for formulations A and B, respectively). The 90%
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confidence intervals for the ratio between both products regarding these metrics were close to
the 0.8 – 1.25 range, considered necessary for bioequivalence. Differences did not reach 20% in any
case and were not determined by a formulation effect, but probably by a patients' variability effect.
Concerning pharmacodynamic features, a high similitude in reticulocyte counts increments until
216 hours and the percentage decrease in serum iron until 120 hours was observed. There were
no differences between formulations regarding the adverse events and their intensity. The more
frequent events were pain at injection site (35.3%) and hypertension (29%). Additionally, further
treatment of the patients with the study product yielded satisfactory increases in hemoglobin and
hematocrit values.
Conclusion:  The formulations are comparable. The newly developed product should be
acceptable for long-term application.
Background
Erythropoietin (EPO) is a sialoglycoprotein hormone
secreted primarily by the mature kidneys in response to
tissue hypoxia and/or red cell mass decrease. It stimulates
erythrocyte production from the blood marrow [1].
Recombinant human EPO has been used since the 80's in
the treatment of anemia associated to end-stage renal dis-
ease. Reports in hemodialysis patients indicate an effec-
tive erythropoiesis increment, ceasing or decrease of
transfusion frequency, and quality of life improvement
[2-6]. However, this treatment is still expensive, not
affordable to developing countries if an extensive use, for
all patients who need it, is sought, considering the same
prevalence as in the United States, where there are cur-
rently 270 000 patients in dialysis [7,8].
Whether multiorigin recombinant proteins can be clini-
cally interchangeable despite coming from different
strains and manufacturing processes is a controversial
matter nowadays [9,10]. If this principle is accepted, then
a study that shows pharmacological similarity between
two products would be enough to indicate its therapeutic
interchangeability, given that they are chemically and
pharmaceutically equivalent as well.
Recently, a recombinant EPO formulation was obtained
in mammalian cells at the Center for Genetic Engineering
and Biotechnology (CIGB in Spanish), Havana. Its phar-
macokinetic, pharmacodynamic and safety profiles were
studied, compared to a similar, previously existing prepa-
ration. The reticulocyte count increments and serum iron
consumption were used as biological action indicators.
Hemoglobin and hematocrit increases after 3-month
treatment was used as an additional efficacy criterion as
well.
Methods
Subjects
Patients, 18–75 years, both sexes, with anemia (hemat-
ocrit ≤  28% or hemoglobin ≤  9 g/dL) due to end-stage
renal disease on hemodialysis (3 sessions per week), who
gave their written, informed consent to participate were
included. The exclusion criteria were: previous EPO treat-
ment; pregnancy or nursing; sepsis or active infection;
non-treated iron deficiency (serum iron <60 mg/dL, ferri-
tin <100 ng/mL, transferrin saturation index <20%); can-
cer; hormonal treatment (except thyroid hormone,
contraceptive and insulin); liver disease (twice and half
the transaminases normal values); diastolic arterial ten-
sion ≥  120 and/or systolic ≥  180 mmHg; severe psychiatric
dysfunction or another limitation that prevented the
patient to give his consent; epilepsy; thrombocytosis (≥
500 000 /mm3); signs of active bleeding; bone marrow
aplasia; active collagen disease; severe hyperparathy-
roidism (serum parathormone > 400 ng/L), and hyperalu-
minemia (serum aluminum > 50 ng/mL). They were
withdrawn from the trial if they died, abandoned volun-
tarily, had severe adverse reactions, were subjected to
renal transplant, used not allowed medications or other
EPO formulations, or if any exclusion criteria arose. The
trial was in compliance with the Helsinki declaration. The
protocol was approved by the Ethics Committee of the
participant institutions and by the Cuban Regulatory
Authority.
EPO formulations
Formulation A (Heberitro, Heber Biotec, Havana) was in
vials containing 2000 IU of human recombinant (rHu)
EPO (produced in Chinese hamster ovarian (CHO) cells
at CIGB, Havana), 2.5 mg serum human albumin, 0.2 mg
polysorbate 20, 2.9 mg NaCl, 4.6 mg NaH2PO4.2H2O, 9.9
mg Na2HPO4, and water for injection to complete 1 mL.
Formulation B consisted in a commercially available
preparation (Eprex, CILAG AG, Switzerland) presented in
pre-filled syringes containing 2000 IU rHuEPO, 0.15 mg
polysorbate 80, 2.192 mg NaCl, 0.580 mg
NaH2PO4.2H2O, 1.115 mg Na2HPO4.2H2O, 2.50 mg gly-
cine, and water for injection to complete 0.5 mL.
Study design
Subjects were distributed according to a computer-gener-
ated random number list, stratified by study center, toBMC Nephrology 2005, 6:5 http://www.biomedcentral.com/1471-2369/6/5
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receive subcutaneously a single dose of 100 IU/Kg of one
of the EPO preparations (A or B) in a parallel design. The
study was double blinded. As the presentation of the
products differed, blinding was kept by loading formula-
tion A vials in syringes coded with the patients' inclusion
numbers, and the nurse that administered the products
did not participate in the rest of the trial.
Patients were hospitalized throughout the study under
strict medical supervision. EPO administrations and
blood sampling were done post-hemodyalisis, when renal
chronic failure patients are closer to their ideal dry weight.
Antipyretic medication was given orally if flu-like symp-
toms or pain at the injection site arose. If blood hyperten-
sion occurred during follow-up patients were treated
according to the investigator's criteria and the precedent
individual treatments.
After the 9 days in-hospital follow-up for the pharmaco-
logical comparison, both groups of patients continued
treatment with formulation A, 30 UI per Kg 3 times per
week, subcutaneously, in order to obtain additional effi-
cacy and safety data for this product. Injections were
administered after the hemodialysis sessions at the
patients' current treatment centers.
Clinical and laboratory evaluations
Blood samples for serum EPO concentration determina-
tions were collected by venipuncture, before and 2, 6, 10,
14, 17, 20, 24, 48, 72, 96, and 120 hours after injection.
Pharmacodynamics was assessed by reticulocyte counts
before and at 48, 72, 120, 144 and 216 hours, and also by
serum iron consumption, before and at 120 and 216
hours. Other hematological determinations (hemo-
globin, hematocrit, red blood cell, platelet, and total and
differential leukocyte counts) were taken as safety varia-
bles, every 24 hours. Alanine aminotransferase (ALT) was
measured before and at the end of the in-patient period
(216 hours). Patients were regularly checked for vital signs
and symptoms, including during the hemodialysis
sessions.
EPO was quantified in serum with a highly sensitive
enzyme immunoassay (EIA) kit (Quantikine® IVD®, R&D
System, Inc, Minneapolis). Serum iron concentrations
were determined by a colorimetric test (NITRO-PAPS,
CENTIS, Havana). Blood chemistry and hematological
counts were done according to usual clinical laboratory
procedures. All laboratory analyses were done blindly.
Anti-EPO antibodies were screened at the end of the fur-
ther treatment and follow-up period by a semiquantita-
tive, "sandwich type", EIA system (EPO; sample; protein A
– horseradish peroxidase conjugate) developed and vali-
dated at the Center for Biological Research, Clinical Labo-
ratory (manuscript in preparation). For this purpose the
blood sample was taken 72 hours after the last EPO
administration. If some sample resulted positive it was
previewed that the patient's baseline sample would be
tested in order to discard spontaneous pre-existing
autoantibodies.
Data analysis
The drug disposition data analysis was performed per
individual by a non-compartmental method with a com-
bined linear/log – linear trapezoidal rule approach. The
linear trapezoidal rule was used up to peak level and the
logarithmic trapezoidal rule thereafter. The first-order rate
constant associated with the curve terminal (log linear)
portion (λ ) and elimination half-life (t1/2) were estimated
by linear regression of the included terminal data points.
Time-to-peak values (Tmax) were determined directly
from the experimental data as the time of maximum
observed level (Cmax) considering the entire curve. Area
under the serum concentration-time curve from 0 to 120
hours (AUC120) was calculated using the linear/log linear
trapezoidal rule. Mean residence time (MRT) was also cal-
culated using the moments of the drug disposition curve.
Parameters that were extrapolated to infinity, such as AUC
(area under disposition curve) and AUMC (area under
first moment of the disposition curve), were computed
based on the last predicted value from the linear regres-
sion performed to estimate λ  and t1/2. In addition, other
pharmacokinetic parameters were also calculated, such as
the systemic clearance (CL), volume of distribution (Vd),
and the peak to area ratio value (CAV = Cmax / AUC). The
apparent absolute bioavailability (F) was estimated using
data from a previously reported study after intravenous
dosing of recombinant EPO as the subcutaneous to intra-
venous AUC ratio [11]. The WinNonlin professional soft-
ware (Version 2.1, Pharsight Inc., 1997, NC, USA) was
used for all these purposes.
Statistical analyses were done using SPSS for Windows
version 11.5. Firstly, to test the homogeneity between the
treatment groups, the Mann-Whitney's U or Student's t
test (depending on the normality assumption) was
applied for quantitative control variables and the chi-
square or Fisher's exact test for the qualitative ones. Phar-
macokinetic parameters were tested for normal distribu-
tion by the Shapiro-Wilk's test and for variance
homogeneity by the Levene's test. To compare formula-
tions the analysis of variance (ANOVA) and the estima-
tion of confidence intervals (90%) of the ratio were used.
Vital signs and laboratory variables were treated using
paired analysis (Student's t test or Wilcoxon's test,
depending on the normality assumption), taking into
account Bonferrony's adjustment for multiple compari-
sons. Regarding pharmacodynamics, formulations were
compared at each time point using the Mann-Whitney's UBMC Nephrology 2005, 6:5 http://www.biomedcentral.com/1471-2369/6/5
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test and the overall characteristics (mean and maximum
effects, and time to reach the latter (T(Rmax)) were evalu-
ated by the Mann-Whitney's U test. Adverse reactions fre-
quencies were compared between formulations using the
Fisher's exact test.
Results
Thirty-four patients were recruited at the seven hospitals
where they regularly received hemodialysis treatment.
Twenty-two of them were included at the National Insti-
tute of Nephrology, Havana, where the trial took place for
them. The other twelve from "Gustavo Aldereguía Lima"
Hospital, Cienfuegos were studied at this same site.
The demographic and baseline characteristics of the
patients as well as their toxic habits and causes of renal
failure are shown in Table 1. Age and weight were highly
variable within each group. Overall, ages ranged from 19
to 75 years and weights from 40 to 87 Kg. Groups were
balanced regarding sex and race. Thirty patients had spec-
ified the cause of renal failure, prevailing diabetes mellitus
and hypertension. The hypothesis of homogeneity
between the groups was accepted.
One patient was excluded from pharmacokinetic and
pharmacodynamic analysis due to a severe adverse event
(ischemic chest pain), 24 hours after the administration
of Formulation B. This patient was only included in safety
evaluations. The rest of the patients complied with the
treatment and follow-up as previewed.
Pharmacokinetic analysis
Except for one patient from each group all had small basal
serum EPO levels (0.7 – 22 mIU/mL in group A and 0.9 –
34 mIU/mL in group B). After rHu EPO administration,
some individual serum concentrations reached 200 mIU/
mL. At 120 hours after the injection, serum EPO concen-
trations had returned to the initial values, so the AUC120
Table 1: Demographic and baseline characteristics of the patients
Variables Formulation A Formulation B Total p
N1 7 1 7 3 4
Age (years) 52 ± 15 (19–72) 52 ± 16 (23–75) 52 ± 15 (19–75) 0.90*
Weight (Kg) 60 ± 12 (40–87) 59 ± 13 (42–83) 59 ± 12 (40–87) 0.82*
Sex Male 11 (64.7%) 8 (47.1%) 19 (55.9%) 0.30∆
Female 6 (35.3%) 9 (52.9%) 15 (44.1%)
Race White 8 (47.1%) 10 (58.8%) 18 (52.9%) 0.73!
Non-white 9 (52.9%) 7 (41.2%) 16 (47.1%)
Smoking 4 (23.5%) 1 (5.9%) 5 (14.7%) 0.33!
Alcohol consumption 4 (23.5%) 1 (5.9%) 5 (14.7%) 0.33!
Coffee drinking 7 (41.2%) 7 (41.2%) 14 (41.2%) 1.00∆
Causes of renal failure
Diabetes Mellitus 7 (46.7%) 6 (40.0%) 13 (43.3%) 0.71∆
Hypertension 5 (33.3%) 4 (26.7%) 9 (30.0%) 1.00!
Other glomerulopathies 1 (6.7%) 1 (6.7%) 2 (6.7%) 1.00!
Cystic disease 1 (6.7%) 3 (20.0%) 4 (5.6%) 0.60!
Data are reported as mean ± standard deviation (range) or number of patients (%).
*: Student's t test; ∆ : chi-square test; !: Fisher's exact test
Average EPO concentration in serum Figure 1
Average EPO concentration in serum. Data correspond to 
patients who received 100 IU/Kg of Heberitro (solid line) or 
Eprex (dashed line) at time 0. Standard deviations are not 
shown for the sake of simplicity of the illustration. Curves 
were not significantly different at any point in a multiple 
determinations ANOVA with Bonferrony's correction.
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obtained covered, in all cases, more than 95% of the AUC
extrapolated to infinite. The average concentration pro-
files obtained for both formulations were very similar
(Figure 1).
Table 2 shows the results of the EPO pharmacokinetic
comparisons. The differences between the means of any of
the pharmacokinetic parameters (except Tmax) did not
exceed the clinically significant level of 20%. The 90%
confidence intervals were generally close to the 0.80 –
1.25 range. A formulation effect was not detected for any
of the parameters.
Pharmacodynamic analysis
Average reticulocyte count increments were very similar
for both formulations, with the same profiles until 216
hours (Figure 2A). The larger increments were approxi-
mately 3 × 109 cells/L. The paired analysis yielded statisti-
cally significant reticulocyte count increments from 120 to
216 hours with respect to time 0. Both formulations
behaved similarly (Table 3). The overall characteristics of
the curves (maximum, means, and time to reach the max-
imum effect) did not show differences likewise (Table 4).
Figure 2B shows the percentage mean reduction in serum
iron. A significant reduction was observed at 120 hours
(paired analysis; Table 3). It was also comparable for both
formulations (43 % for A and 36 % for B). A smaller per-
centage reduction appeared at 216 hours for formulation
B. Quantitative analysis of the data also evidenced similar
performance for both products (Table 4).
Safety analysis
Twenty-three patients (67.6%) presented at least one
adverse event during the study, 11 that received Formula-
tion A (64.7%) and 12 Formulation B (70.6%). There
were no differences between formulations concerning the
adverse events, except for edemas, which were signifi-
cantly more frequent with Formulation B (Table 5). The
more frequent adverse events were pain at the site of injec-
tion (35.3%) and hypertension (29%). The events were
mild to moderate and well controlled in general. Just one
patient had a serious episode of angina 24 hours after For-
mulation B administration. This event was considered as
"not related" with the product because the single dose
applied does not justify an erythrocyte increment that
could lead to this syndrome. Additionally, this patient
had antecedents of ischemic cardiopathy. Differences in
vital signs and other laboratory evaluations were not sig-
nificant between formulations (data not shown).
Hemoglobin and hematocrit were not affected with the
single dose administered.
Further follow-up
Further treatment with formulation A induced significant
increases in hemoglobin and hematocrit (Table 6). All the
patients, except 4 from both groups, were considered as
responders since they increased at least the hematocrit in
5% and/or hemoglobin in 2 g/dL, after 3 months of treat-
ment. During this period, the EPO-related adverse events
were fever, chills and headache, each one recorded in one
patient. No serum anti-EPO antibodies were detected in
any patient.
Discussion
This trial indicates that the compared formulations have
similar pharmacokinetic and pharmacodynamic charac-
teristics. The dose selected was adequate, since EPO titers
in serum were easily detected and the treatment was quite
well tolerated. Differences between formulations were not
statistically significant for any of the calculated parame-
ters. Regarding serum EPO profiles, differences were not
Table 2: Pharmacokinetic parameters calculated from the EPO concentration in serum
Parameter Formulation A N = 17 Formulation B N = 16 Difference (%) p 90 % CI
AUC120(mUI·h/mL) 4500 ± 2281 4654 ± 2221 5.1 0.49 (0.71 – 1.27)
AUC (mUI·h/mL) 4667 ± 2319 4918 ± 2113 3.3 0.66 (0.71 – 1.32)
Cmax (mUI/ml) 119.1 ± 56.4 119.7 ± 60.5 0.5 0.96 (0.73 – 1.35)
Tmax (h) 13.9 ± 9.9 18.1 ± 14.9 23.2 0.08 -
λ (h-1) 0.040 ± 0.018 0.037 ± 0.015 10.8 0.49 (0.89 – 1.32)
t1/2 (h) 20.0 ± 7.9 22.5 ± 12.1 11.1 0.29 (0.69 – 1.14)
CAV 0.027 ± 0.008 0.024 ± 0.007 8.0 0.38 (0.94 – 1.31)
F 0.29 ± 0.14 0.31 ± 0.14 6.4 0.53 (0.75 – 1.17)
MRT (h) 33.9 ± 10.7 42.3 ± 20.8 19.8 0.15 -
CL (mL/h·Kg) 6.3 ± 0.3 6.3 ± 0.4 0.5 0.55 (0.98 – 1.03)
Vd (mL/Kg) 182 ± 74 202 ± 107 10.0 0.67 (0.70 – 1.15)
Data are reported as mean ± standard deviation
CI: confidence intervals of the mean ratio; for Tmax and MRT, 90 %CI could not be estimated for a parallel design.
p: ANOVA between groupsBMC Nephrology 2005, 6:5 http://www.biomedcentral.com/1471-2369/6/5
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Pharmacodynamic variables Figure 2
Pharmacodynamic variables. Data correspond to patients who received 100 IU/Kg of Heberitro (solid line) or Eprex (dashed 
line). (A): average reticulocyte counts increments; (B): percentage mean reduction in serum iron. Standard deviations are not 
shown for the sake of simplicity of the illustration.
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statistically significant at any time point; the curves
overlap. The fact that more than 80% of the AUC could be
covered by the AUC120 obtained indicates that internal
validity of the data is high. For pharmacokinetic parame-
ters, except for CL, the 90%confidence intervals of the
ratio between formulations were outside the 0.80 – 1.25
limits accepted for bioequivalence, but close to it. Taking
into consideration that it was a parallel trial, using bio-
technological products, in patients with anemia due to
end-stage renal disease on hemodialysis and not in
healthy subjects, a higher inter-individual variability
could be expected. For example, patients' age range was
quite wide. Then, a more flexible approach for bioequiva-
lence criterion, at least 0.7 – 1.3, could be justified.
This variability occurred in the calculated pharmacoki-
netic parameters as well. Main parameters such as AUC,
AUC120 or Cmax showed very small punctual differences
(5% or less), but standard deviations, although similar
between treatment groups, were large (coefficients of var-
iation around 50%). Consequently, it was not possible
that 90% confidence intervals fulfill with the 0.80 – 1.25
range.
This kind of study is usually done in healthy volunteers
[12-15], since under a more controlled situation a smaller
variability of the results is obtained. However, in this case
investigators preferred to do it in the target patients since
their renal failure condition would have considerable
influence on EPO pharmacokinetics and
pharmacodynamics. Besides, there was a risk due to EPO-
dependent blood viscosity increase and hypertension
[16], and Ethics Committees could have been reluctant to
approve the protocol. In fact, there is very little safety
Table 3: Reticulocyte Counts Increments and Percentage Reduction of Serum Iron during the study
Formulation A N= 17 Formulation B N= 16 p A vs. B
Reticulocyte counts Increments (×109/L) (p for paired test) significance level p = 0.010
T48 -T0 2.5 ± 4.2 (0.109) 2.4 ± 3.4 (0.028) 0.694
T72 -T0 2.4 ± 3.4 (0.078) 2.5 ± 3.7 (0.011) 0.520
T120 -T0 2.8 ± 2.9 (0.001) 2.9 ± 2.8 (0.002) 0.986
T144 -T0 3.2 ± 2.8 (<0.001) 2.8 ± 2.7 (0.002) 0.552
T216-T0 2.8 ± 2.2 (< 0.001) 2.5 ± 2.4 (0.001) 0.407
Serum iron % Reduction (p for paired test) significance level: p = 0.025
T120 -T0 42.7 ± 20.5 (0.001) 35.7 ± 17.1 (0.001) 0.205
T216-T0 37.0 ± 21.4 (0.050) 17.3 ± 19.4 (0.541) 0.805
Data are reported as mean ± standard deviation.
Paired tests vs. baseline were done by the Wilcoxon's test and comparison between formulations at each time by the Mann-Whitney's U test.
Table 4: Overall quantitative analysis of reticulocyte counts (×109/L) and serum iron percentage reduction
Analysis Formulation A N= 17 Formulation B N= 16 p (Mann-Whitney's U test)
Reticulocyte counts (×109/L)
Mean 2.7 ± 2.9 2.6 ± 2.7 0.678
Maximum 4.3 ± 3.9 3.9 ± 3.9 0.397
T(Rmax) (hours) 146.8 ± 59.9 130.5 ± 51.8 0.201
Serum iron percentage reduction
Mean 39.8 ± 18.4 26.5 ± 13.1 0.265
Maximum 47.3 ± 19.2 39.2 ± 15.2 0.355
T(Rmax) (hours) 160.9 ± 61.6 148.5 ± 53.5 0.365
Data are reported as mean ± standard deviation.
These data correspond to the 34 patients who received one of the EPO formulations.
T(Rmax): Time to reach maximum response.BMC Nephrology 2005, 6:5 http://www.biomedcentral.com/1471-2369/6/5
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information in the above cited reports on healthy
volunteers.
On the other hand, for bioequivalence trials crossover
treatment groups with an inter-treatment washout period
are preferred. This leads to estimate and to reduce the
individual variability as the main variation source; there-
fore, statistical analyses have more power. However, ane-
mic patients with renal chronic failure need continuous
EPO for their red cell synthesis. To submit them to a wash-
out period implied to wait again for the irruption of ane-
mia and this procedure was not ethically acceptable. After
this trial, the patients continued EPO treatment under
phase II trial conditions. They were monitored during this
period and the results show that the study product was
effective in increasing their hemoglobin and hematocrit
values significantly.
In some situations, the intra and inter-subject variability
can be equally or more important than the variation from
an innovator product to a similar. In fact, the importance
of the individual bioequivalence concept is recently being
Table 5: Frequency of adverse events during the study
Variable Formulation A N = 17 Formulation B N = 17 p (Fisher's test)
Adverse events Yes 11 (64.7%) 12 (70.6%) 1.00
No 6 (35.3%) 5 (29.4%)
Specific adverse event Chest pain 0 1 (5.9%) 0.50
TGP increase 1 (5.9%) 0 0.50
Tachycardia 1 (5.9%) 4 (23.5%) 0.17
Headache 4 (23.5%) 3 (17.6%) 0.50
Abdominal pain 0 1 (5.9%) 0.50
Asthenia 1 (5.9%) 3 (17.6%) 0.30
Diarrhea 0 2 (3.6%) 0.24
Dyspnea 0 2 (3.6%) 0.24
Somnolence 0 1 (1.8%) 0.50
Neck pain 1 (5.9%) 0 0.50
Hypertension 6 (35.3%) 4 (23.5%) 0.35
Pain at site of injection 6 (35.3%) 6 (35.3%) 1.00
Bone pain 0 1 (5.9%) 0.50
Edema 0 6 (35.3%) 0.009*
Fever 2 (11.8%) 5 (29.4%) 0.20
Hypotension 5 (29.4%) 2 (11.8%) 0.20
General malaise 1 (5.9%) 1 (5.9%) 0.50
Pneumonia 0 1 (5.9%) 0.50
Pruritus 1 (5.9%) 3 (17.6%) 0.30
Chills 2 (11.8%) 2 (11.8%) 0.70
Vomiting 3 (17.6%) 6 (35.3%) 0.22
Data are presented as number of individuals with each adverse reaction (%).
Table 6: Efficacy evaluation during further follow-up. Both groups of patients received formulation A, 30 UI per Kg 3 times per week, 
subcutaneously.
Variable Day Group A Group B
Hemoglobin (g/dL) 0 8.8 ± 1.7 9.0 ± 1.4
90 10.5 ± 1.4 11.4 ± 1.6
p (90 vs. 0) 0.027 0.004
Hematocrit (%) 0 25.6 ± 4.4 26.9 ± 5.9
90 35.5 ± 3.2 36.4 ± 5.1
p (90 vs. 0) < 0.001 0.001
Data are reported as mean ± standard deviation.
Paired tests vs. day 0 were done by paired t test.BMC Nephrology 2005, 6:5 http://www.biomedcentral.com/1471-2369/6/5
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claimed, which would allow the scaling of the established
intervals based on the individual comparison and the sub-
ject – formulation interaction [17,18].
For both formulations, Tmax was within the 12 – 18
hours reported for EPO, although a great variability is
reported for this variable in renal patients [11,19-23].
Tmax is a discrete variable that depends on the experimen-
tal design so it cannot be interpreted as a continuous value
and thus the small punctual difference observed looses
practical significance. The European Guidelines recom-
mend its analysis by non-parametric procedures [24]. Val-
ues for F, t1/2 and MRT were according to other studies, 18
– 49%, 15–25 hours and 25 – 45 hours, respectively
[11,12,19,25-28]. Cmax, although continuous, depends
much on the times at which samples are taken. Several
reports propose to expand its bioequivalence range up to
30% [29-31], and in some cases this wider 90% CI can be
accepted [24]. Cmax is considered either as a magnitude
or as a rate of absorption parameter but does not accu-
rately describe either process. Other parameters such MRT
and CAV best describe absorption rates [32,33].
The results of pharmacodynamic variables (reticulocyte
counts and serum iron) predict a possible therapeutic
equivalence between the formulations, given their simili-
tude. It is not possible to achieve significant increments in
hematocrit or hemoglobin (main clinical endpoints) with
a single EPO dose, but the reticulocyte count increase cor-
relates with the clinical effect. Stable increments in hemo-
globin and hematocrit are only reached after prolonged
treatment, as was found in these patients. A multiple dose
design is costly and complicated for this kind of trial. It is
only justified for drugs with specific pharmacological
characteristics (e.g. non-linear pharmacokinetics). Addi-
tionally, any eventual blood transfusion, which is often in
these patients, would interfere with the results.
The pharmacodynamic curves were not well characterized
by using pharmacokinetic-like parameters due to ethical
reasons, since some patients needed to be transfused.
Additionally, EPO receptor-binding dependent biological
effects attain their maximum several days after adminis-
tration, when EPO serum levels have returned to baseline
[14,34]. Therefore the dissipation phases of the effects
were not well covered.
The integration of pharmacokinetic and pharmacody-
namic characterizations into drug development provides
a scientific framework for its rational and efficient appli-
cation [35,36], as has already been done for EPO in ath-
letes [37]. Repeated administration of EPO to healthy
subjects was more effective in stimulating a reticulocyte
response than single-dose administration of the same
total amount [14]. However, similar pharmacodynamic
effects with dissimilar doses or schedules were also
reported in healthy individuals [38].
Concerning safety, treatment was well tolerated, except for
an episode of angina. The number of patients that pre-
sented adverse events was almost the same for both
formulations. Many adverse events were observed during
hemodialysis sessions or few hours after. Thus, it is very
difficult to predict if those events were EPO- or dialysis-
related. The most frequent event observed with recom-
binant EPO treatment is hypertension, but headache, flu-
like syndrome, rash, vascular thrombosis and others can
appear [2-4,16,39,40]. As a rule they appear after longer
treatments, higher doses or due to a rapid hematocrit
increase. During the follow-up period very few drug-
related adverse events appeared, mostly mild.
The introduction of "biogenerics" to the market is a con-
troversial matter nowadays. Two recombinant EPO mole-
cules could be similar from the physicochemical point of
view, but it is always possible that differences in
producing strains and/or manufacturing processes turn
out into small differences in composition (isoforms, host
contaminants, ingredients, etc.) that could have clinical
repercussion in terms of safety or efficacy. However the
"process = product" dogma has been broken in the last
years and the attitude of regulatory agencies is more
towards accepting, on a case by case basis, the possibility
of interchangeability of biological – derived products,
mostly when they are highly purified and characterized
molecules. In that sense, some examples exist already in
the market such as different insulins, somatotrophins,
and CHO cells-derived interferon beta from different
manufacturing sites [41]. In fact, two EPREX formulations
with different stabilizers were pharmacokinetically equiv-
alent [42]. The different EPO preparations have been in
the clinics for several years and substantial information
concerning their safety and efficacy in their various indi-
cations has been gathered. It is thus unlikely that any
unexpected general safety or efficacy issue can arise from
the use of a well characterized EPO preparation.
The main concern has been the development of anti-EPO
neutralizing antibodies and consequently, aplastic ane-
mia [43]. This phenomenon has been related to packaging
and storage conditions [44], but should be monitored
carefully since it still appears, even at very low frequency.
Canadian authors found very low frequency and con-
cluded that a general screening is not justified, but only on
resistant patients [45]. No serum anti-EPO antibodies
were detected after 3 months of treatment in our study.
However this is still a short period to derive any conclu-
sion on the immunogenicity of the molecule.BMC Nephrology 2005, 6:5 http://www.biomedcentral.com/1471-2369/6/5
Page 10 of 11
(page number not for citation purposes)
The possibility that a home-made EPO reaches the market
in a developing country is an attractive alternative in order
to expand its use, given the high prices that the proprietary
drugs have. The cost of EPO treatment is approximately
500 USD per month [46] in the United States using com-
mercially available products. For example, in Cuba (11
million inhabitants) there are approximately 2000 renal
patients in hemodialysis, but this figure should increase
after an investment policy where new hemodialysis facili-
ties are set up throughout the country. If EPO had to be
imported to cover this population, the country should
spend not less than 12 million USD per year for this pur-
pose (not counting additional freight and commercial
charges). To use the national product would permit a sig-
nificant impact on health care, even if the "biogenerics"
concept is not accepted. In the case of newly developed
EPO preparations, the comparable pharmacokinetics and
pharmacodynamics data can be the basis for its introduc-
tion in the national market. Then further efficacy informa-
tion can be gathered as well as immunogenicity
monitoring.
Conclusion
Given that both formulations have similar pharmacoki-
netic, pharmacodynamic and short-term safety profiles,
the newly developed product can be used in the clinics,
with an appropriate efficacy, safety and immunogenicity
monitoring.
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